Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us ![]()
About
Not Confirmed
Not Confirmed
24-26 February, 2026
BIO Partnering at JPMBIO Partnering at JPM
Not Confirmed
Not Confirmed
12-15 January, 2026
Biotech ShowcaseBiotech Showcase
Not Confirmed
Not Confirmed
12-14 January, 2026
List your booth number for exhibitions, ask us
CONTACT DETAILS






Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Industry Trade Show
Not Confirmed
24-26 February, 2026
BIO Partnering at JPMBIO Partnering at JPM
Industry Trade Show
Not Confirmed
12-15 January, 2026
Biotech ShowcaseBiotech Showcase
Industry Trade Show
Not Confirmed
12-14 January, 2026
Digital content

05 Dec 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/12/05/3200990/0/en/ORIC-Pharmaceuticals-Reports-Inducement-Grants-under-Nasdaq-Listing-Rule-5635-c-4.html

05 Dec 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/12/06/3201024/0/en/ORIC-Pharmaceuticals-Presents-Potential-Best-in-Class-Profile-for-Enozertinib-with-Robust-Systemic-and-CNS-Activity-in-1L-and-2L-NSCLC-Patients-with-EGFR-Exon-20-Mutations-at-the-E.html

03 Dec 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/12/03/3199316/0/en/ORIC-Pharmaceuticals-Announces-Enozertinib-ORIC-114-Late-Breaking-Oral-Presentations-in-EGFR-Atypical-and-EGFR-exon-20-NSCLC-at-the-ESMO-Asia-Congress-2025.html

01 Dec 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/12/01/3196976/0/en/ORIC-Pharmaceuticals-Announces-Enozertinib-ORIC-114-Poster-Presentation-in-HER2-exon-20-NSCLC-at-the-ESMO-Asia-Congress-2025.html

24 Nov 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/11/24/3193927/0/en/ORIC-Pharmaceuticals-to-Participate-in-the-8th-Annual-Evercore-Healthcare-Conference.html

13 Nov 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/11/13/3187843/0/en/ORIC-Pharmaceuticals-Announces-Completion-of-Dose-Exploration-Portion-of-ORIC-944-Phase-1b-Clinical-Trial-and-Continues-to-Demonstrate-Potential-Best-in-Class-Efficacy-and-Safety.html
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE